GNOM ETF — Holdings & Analysis

The Global X Genomics & Biotechnology ETF (GNOM) is an exchange-traded fund that seeks to replicate the price and yield performance of the Solactive Genomics Index. This index is designed to track the performance of companies that are involved in the genomics and biotechnology industries. GNOM provides investors with targeted exposure to companies engaged in gene editing, DNA sequencing, and other genomic advancements. As of 2026-03-15, GNOM has an AUM of $0.05 billion and holds 49 different stocks, offering a focused approach to investing in the genomics revolution. Past performance does not guarantee future results.

The expense ratio for the Global X Genomics & Biotechnology ETF (GNOM) is 0.50%. This means that for every $1000 invested in the fund, $5.00 is used to cover the fund's operating expenses. While this is higher than some broad market ETFs, it is important to consider the specialized nature of the fund's investment strategy. The expense ratio should be evaluated in the context of the potential returns and the specific exposure that GNOM provides to the genomics and biotechnology sectors. Past performance does not guarantee future results.

As of 2026-03-15, the top holdings in the Global X Genomics & Biotechnology ETF (GNOM) are concentrated in leading companies within the genomics and biotechnology industries. The top three holdings are Moderna Inc (MRNA) at 7.86%, Praxis Precision Medicines Inc Ordinary Shares (PRAX) at 6.23%, and Arrowhead Pharmaceuticals Inc (ARWR) at 5.69%. These companies represent a significant portion of the fund's assets and reflect its focus on innovative healthcare and biotechnology firms. Investors should review the complete list of holdings to understand the fund's overall composition. Past performance does not guarantee future results.

Whether GNOM is a suitable long-term investment depends on an individual's investment goals, risk tolerance, and time horizon. GNOM provides targeted exposure to the genomics and biotechnology sectors, which have the potential for long-term growth due to advancements in personalized medicine and gene editing. However, the fund's concentrated portfolio and sector-specific focus introduce risks that investors should carefully consider. With a beta of 1.95, GNOM exhibits high volatility, which may not be suitable for all investors. Investors should conduct thorough research and consult with a financial advisor before making any investment decisions. Past performance does not guarantee future results.

GNOM differentiates itself through its specific focus on genomics and biotechnology companies. While other healthcare or biotechnology ETFs may offer broader exposure, GNOM provides a more targeted approach to investing in the genomics revolution. GNOM has an expense ratio of 0.50% and an AUM of $0.05 billion. When comparing GNOM to similar ETFs, factors may be worth researching such as expense ratios, portfolio composition, tracking error, and historical performance. It is important to assess whether GNOM's specialized strategy aligns with their investment objectives and risk tolerance. Past performance does not guarantee future results.

Yes, GNOM does pay dividends. As of 2026-03-15, the dividend yield for the Global X Genomics & Biotechnology ETF (GNOM) is 1.30%. It's important to note that dividend yields can fluctuate based on market conditions and the performance of the underlying holdings. Investors seeking income may find GNOM's dividend yield attractive, but should also consider the fund's overall investment strategy and potential for capital appreciation. Past dividend payouts are not indicative of future dividend payments. Past performance does not guarantee future results.